Vanguard Global Advisers
SPRB

Vanguard Global Advisers’s Spruce Biosciences SPRB Stock Holding History

Vanguard Global Advisers’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.4K Hold
452
– – ﹤0.01% 3271
2026
Q1 		$29.5K Buy
+452
New +$31.2K ﹤0.01% 3202

Other funds holding SPRB

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return

Vanguard Global Advisers's SPRB Position: Q2 2026 in Review

Vanguard Global Advisers held its Spruce Biosciences (SPRB) position steady in Q2 2026 at 452 shares worth $24.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3271.

Vanguard Global Advisers first reported a position in SPRB in Q1 2026 and has held it in 2 quarters since. The position peaked at $29.5K in Q1 2026. 57 funds tracked by Wall St. Rank hold SPRB as of Q2 2026.

  • Vanguard Global Advisers held 452 shares of Spruce Biosciences worth $24.4K as of Q2 2026.
  • Vanguard Global Advisers left its Spruce Biosciences share count unchanged in Q2 2026.
  • Spruce Biosciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3271 holding.
  • Vanguard Global Advisers first reported a position in Spruce Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Spruce Biosciences position peaked at $29.5K in Q1 2026.
  • 57 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.